Skip to main content
Log in

Elevated clozapine serum levels in combination with perazine

  • Letter to Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Baumann P, Hiemke C, Ulrich S et al (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:243–265

    Article  PubMed  CAS  Google Scholar 

  • Frick A, Kopitz J, Bergemann N (2003) Omeprazole reduces clozapine plasma concentrations. A case report. Pharmacopsychiatry 36:121–123

    Article  PubMed  CAS  Google Scholar 

  • Haen E, Greiner C, Bader W, Wittmann M (2008) Expanding therapeutic reference ranges using dose-related reference ranges. Nervenarzt 79:558–566

    Article  PubMed  CAS  Google Scholar 

  • Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279–281

    Article  PubMed  CAS  Google Scholar 

  • Hiemke C, Baumann P, Bergemann N et al (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195–235

    Article  Google Scholar 

  • Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319–326

    Article  PubMed  CAS  Google Scholar 

  • Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21:569–574

    Article  PubMed  CAS  Google Scholar 

  • Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392–394

    Article  PubMed  Google Scholar 

  • Schaller G, Jacobi A, Rotter A, Kornhuber J, Hillemacher T (2009) Perazine elevates clozapine serum levels by inhibiting hepatic metabolism. Prog Neuropsychopharmacol Biol Psychiatry 33:908–909

    Article  PubMed  CAS  Google Scholar 

  • Störmer E, Brockmöller J, Roots I, Schmider J (2000) Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 151:312–320

    Article  Google Scholar 

  • Wójcikowski J, Daniel WA (2009) Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism—an in vitro study. Pharmacol Rep 61:851–858

    PubMed  Google Scholar 

Download references

Conflict of interest

No funding and no conflict of interest for any or the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Fischer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fischer, M., Unterecker, S., Deckert, J. et al. Elevated clozapine serum levels in combination with perazine. Psychopharmacology 226, 623–625 (2013). https://doi.org/10.1007/s00213-013-3007-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-013-3007-y

Keywords

Navigation